NanoBio Corp. will get an initial contract of $5.5 million and up to $5 million more to devleop its nanoemulsion technology to improve the performance of flu vaccines.
NanoBio Corp. announced the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy meeting showing the safety and effectiveness of a vaccine for the prevention of respiratory syncytial virus, enhanced by the company’s nanoemulsion technology.
NanoBio Corp. Tuesday said that it is presenting new data demonstrating positive pre-clinical results for its intramuscular respiratory syncytial virus vaccine at the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research.
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions nad groiups
NanoBio Corp. announced Monday it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus Symposium taking place Sept. 27-30 in Santa Fe, N.M.
Nanobio Corp. Thursday announced a preclinical collaboration with a subsidiary of Merck & Co. Inc. focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).
NanoBio Corp. announced Wednesday that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus vaccine have shown strong immunity effects, paving the way for more studies of the nanoparticle-based technology.
Ann Arbor-based NanoBio Corp. last week announced a licensing agreement with the National Institutes of Health that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.
Ann Arbor-based NanoBio Corp. says newly published experimental data shows that its nanoemulsion-based flu vaccine has elicited robust immunity to the flu in animal tests on ferrets.
Building upon a series of successful preclinical and clinical studies, Ann Arbor-based NanoBio Corp. Tuesday announced the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant.